Authors Posts by Head Editor

Head Editor

5296 POSTS 18 COMMENTS

0 1349

Mentor Capital Selects Colorado Auditor for the Next Phase of Its Medical Marijuana and Cannabis Business

BF Borgers CPA PC of Lakewood, CO to Replace Albert Wong & Co., LLP as Company’s Public Accountant

SAN DIEGO–(BUSINESS WIRE)–

Mentor Capital, Inc. (OTC Markets: MNTR) announced that it has engaged BF Borgers CPA PC as its new public accounting firm and has filed a Form 8-K with the SEC through the EDGAR system detailing this move to the Colorado based auditor. Mentor CEO Chet Billingsley observes, “Given our ongoing medical marijuana and cannabis focus, it made sense to move to an auditor in a state where many cannabis businesses are active and marijuana has been legalized at the state level. This further supports our earlier 2014 actions to progressively step up our reporting levels from limited information, to current information, and with the recent completion of two years of financial audits and an initial Form 10 filing, toward being fully reporting with the SEC.”

The Form 8-K, which indicates that there were no disagreements with the previous auditor, Albert Wong & Co. of New York and Hong Kong, nor any reportable events, can be referenced through the SEC’s EDGAR system at:

https://www.sec.gov/edgar/searchedgar/companysearch.html

Inputting the company name, Mentor Capital, Inc. or the company’s CIK code which is 0001599117, will bring up the report. The Form 8-K will also be able to be viewed at the company’s web site: www.MentorCapital.com at the Investor’s Corner section under the Disclosures tab.

About Mentor Capital: By acquisition or stock purchase, Mentor Capital, Inc. seeks to invest in leading cannabis companies. Additional important information for investors and founders seeking expansion funding is presented at the company website above.

This press release is neither an offer to sell, nor a solicitation of offers to purchase, securities.

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the federal securities laws, including statements concerning financial projections, financing activities, corporate combinations, product development activities and sales and licensing activities. Such forward-looking statements are not guarantees of future results or performance, are sometimes identified by words of condition such as “should,” “could,” “expects,” “may,” or “intends,” and are subject to a number of risks and uncertainties, known and unknown, that could cause actual results to differ materially from those intended or anticipated. Such risks include, without limitation: nonperformance of investments, partner and portfolio difficulties, potential delays in marketing and sales activities, problems securing the necessary financing to continue operations, problems encountered in commercializing cannabis products, potential of competitive products, services, and technologies, difficulties experienced in product development, difficulties in recruiting knowledgeable personnel and potential problems in protecting intellectual property. Further information concerning these and other risks is included in the Company’s Form 10 filing which, along with other very important information about the Company, can be found here:

http://mentorcapital.com/disclosures/

The Company undertakes no obligation to update or revise such forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Contact:
Mentor Capital, Inc.
Chet Billingsley, CEO
(760) 788-4700

0 1471

Agritek Holdings, Inc. Announces Execution of Contract With Blue Line Protection Group for Colorado Cultivation Campus

Blue Line Protection Group to Supply Armed Security, Armored Transportation Services and Banking Compliance Solutions for Licensed Tenants of Agritek Facility

LOS ANGELES, CA–(Marketwired – December 05, 2014) – Agritek Holdings, Inc.(AGTK) (http://www.Agritekholdings.com), a fully reporting company on the OTCQB and leader in Compassionate Care Technology and indoor/outdoor agricultural solutions for the medicinal marijuana industry, today announced that the Company has executed contracts with Blue Line Protection Group Inc. (BLPG) to provide security and transportation services on behalf of the Company’s Colorado cultivation facility and campus located near Pueblo, Colorado. In Pueblo County, the Company currently has 40 acres under a long term lease and owns 80 acres under a land purchase agreement and is currently contemplating acquiring the leased 40 acres as part of a 260 acre land purchase agreement.

Blue Line will provide security services on behalf of approved and state-licensed tenants of the campus presently under development in Pueblo, Colorado. Blue Line will act as a consultant and joint-venture partner providing knowledge of security issues including security measures of fencing, perimeter cameras, guard services, armored car and banking solutions.

“We are extremely pleased to work with the experienced and respected team at Blue Line Protection and have them as a partner in our Colorado facility,” said B. Michael Friedman, CEO of Agritek Holdings, Inc. Most of the staff we are employing through Blue Line are military, law enforcement and special forces veterans that are trained professionals in all matters of security for these type of operations. “We’re excited to begin operations with Agritek Holdings,” said Sean Campbell, Blue Line’s Chief Executive Officer. “This new contract secures Blue Line as the premier transportation and security provider for the lawful cannabis industry and further consolidates our position of dominance in Colorado.”

About Agritek Holdings, Inc.
Agritek Holdings, Inc. (www.Agritekholdings.com), a fully reporting Company and pioneer within the medicinal marijuana space provides innovative patient and agricultural solutions seeks to be the leader in Compassionate Care Technology for the medicinal marijuana industry. Agritek Holdings provides real estate management and health and wellness product lines including through its’ wholly owned subsidiary Agritek Holdings Inc. does not directly grow, harvest, or distribute or sell cannabis or any substances that violate United States law or the Controlled Substances Act, nor does it intend to do so in the future.

About Blue Line Protection
Blue Line Protection Group provides secured transportation, state and federal regulatory compliance, security consultation and training, and professional protection services to high-value asset industries. The company’s security operators, investigations personnel and consulting staff are highly trained professionals with significant experience in law enforcement and the United States armed forces. For more information, visitwww.BlueLineProtectionGroup.com.

FORWARD-LOOKING DISCLAIMER:

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Agritek Holdings, Inc. to be materially different from the statements made herein.

Contact:
Agritek Holdings, Inc.
561.249.6511

www.Agritekholdings.com
info@Agritekholdings.com

0 1199

mCig(R) Appoints Michael Snody to the Position of Chief Research and Development Officer

BEVERLY HILLS, Calif. (GLOBE NEWSWIRE) — mCig(R), Inc. (MCIG) (“mCig”), a technology company that owns, manufactures, and distributes the mCig(R), VitaCig(R), and Vapolution products, is pleased to announce the appointment of Michael Snody to the position of Chief Research and Development Officer. Mr. Snody will run the company’s new metalworks and hardware division and this will be the first division that concentrates on American-made products.

To this point, mCig Inc. has focused primarily on delivering vaporizers and vape pens at a disruptive price. From here, mCig Inc. plans to move into processing plant materials, manufacturing and distributing equipment used to process plant materials, and incorporating cannabinoids into our product lines. The company’s mission is to transition into a holding company with a core of profitable divisions that will focus on future potential in this ever expanding industry and provide worthwhile employment opportunities to the American economy. With the metalworks and hardware division, the company plans on dominating vaporization and its associated hardware market while incorporating these products into mCig’s arsenal.

In his new capacity, Mr. Snody will draw on his exceptional materials and design expertise developed over a diverse 34-year career. His unique understanding of specialty alloys such as titanium, zirconium, and powdered steels, as well as space-age composites will form the basis of a high-performance, luxury product line of vaporizers and accessories made in the United States. Michael will be responsible for developing and sourcing new mCig products for the rapidly expanding global market.

Mr. Snody, a native of Corpus Christi, Texas, comes to mCig after a lengthy career in design and fabrication. Most recently, Mr. Snody’s own company, Mike Snody Knives Unlimited, was responsible for designing and crafting some of the world’s most sought-after custom performance cutlery. In addition to his own custom pieces, Michael has also contracted to design and produce knives in conjunction with industry leaders including Benchmade Knives, Heckler & Koch Firearms, and the National Rifle Association. Currently, several of Mr. Snody’s designs are being produced by Ka-Bar Knives. Michael’s signature work is marked by his exceptional ability to work with a wide variety of rare and high-performance materials, including titanium alloys, carbon fiber, petrified dinosaur bone, meteorite, Damascus steels, and the most high-performance stainless steels available. Over the course of the past 15 years, Mr. Snody has developed a loyal international following, with customers regularly paying in excess of $5,000 for each custom Snody knife. His fan base includes a vibrant community of followers on YouTube, Facebook, and over 14,000 followers on Instagram.

Prior to his success in the custom cutlery arena, Michael built a stellar reputation as an engineering consultant for Exxon Co. USA. Working throughout the United States, Russia, Mexico, Japan, and other countries around the world, Mr. Snody provided a wide range of services, including general project management, code and specification enforcement, and contractor scheduling. In this capacity, Exxon relied on Michael’s commitment, as well as his depth and breadth of knowledge in managing several multi-million dollar projects simultaneously in different geographical regions worldwide. Mr. Snody began his career in the energy sector as an ASME certified welder / fabricator in oil refineries, chemical plants, and on pipelines and offshore drilling platforms. He is an AWS certified welding inspector and educator. He holds API certifications 653 and 570 for tank and pipeline inspection. Michael has an associate’s degree in fabrication from Del Mar Technical College.

After interfacing with Mr. Snody at industry trade shows, mCig Management developed a professional relationship with Mr. Snody, resulting in the offering of the position of Chief Research and Development Officer. mCig believes that Mr. Snody is an ideal fit for this position, and that his experience, dedication, and vision will elevate the mCig product line to an even higher level of quality and craftsmanship.

“It is an honor to be a part of mCig. I am passionate about this product line, and have personally used mCig products to successfully kick a decades-long tobacco habit. This is an exciting time for this company and this industry, and I am thrilled to be a part of it with an industry leader like mCig,” said Mr. Snody.

Michael will operate out of his Colorado manufacturing facility, creating prototypes, sprint runs, as well as producing his upscale, American-Made Snody Highroller(TM) line of products.

About mCig, Inc.

mCig, Inc. (MCIG) is a technology company focused on two long-term secular trends sweeping the globe: (1) The decriminalization and legalization of marijuana for medicinal or recreational purposes (2) The adoption of electronic vaporizing cigarettes (commonly known as “eCigs”) by the world’s 1.2 Billion smokers. The company manufactures and retails the mCig(R) line of products including the mCig(R) 2.0 — the world’s most affordable vaporizer priced at only $10 to the mCig(R) 3.0 — one of the most advanced personal vaporizers on the market. Designed in the USA — the mCig(R) provides a superior smoking experience by heating plant material, waxes, and oils delivering a smoother inhalation experience. The company also owns Vapolution, Inc. which manufactures and retails home-use vaporizers such as the Vapolution 3.0. Through its wholly owned subsidiary, VitaCig, Inc. the company manufactures and retails the VitaCig(R), a $5 nicotine-free eCig that delivers a water-vapor mixed with vitamins and natural flavors. See more at: http://www.mCig.org/, www.Vapolution.com, and www.VitaCig.org

The company believes that a well regulated marijuana industry is emerging as more states follow the lead of Washington and Colorado in legalizing marijuana. A similar trend is developing within the eCig industry following the first acquisition of an electronic cigarette brand (Blucigs) by a traditional tobacco company Lorillard Inc. for $135 million followed by another acquisition in February 2014 by Altria Group Inc. of Green Smoke for $150 million. Wells Fargo analyst Bonnie Herzog estimates that eCig sales may rise from $1 Billion in 2013 to $10 billion over the next three years.

mCig, Inc. (MCIG) has positioned itself as a first mover at the intersection of these two trends and hopes to create shareholder value by making the mCig(R) one of the leading choices for electronic consumption of plant material. – See more at: http://www.mcig.org/investors/investor-opportunity-subpage/

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.

Contact:

Paul Rosenberg
CEO
1 (425) 652-5946

0 1490

OrganiGram Announces Brokered Private Placement

MONCTON, NEW BRUNSWICK–(Marketwired – Dec 5, 2014) – OrganiGram Holdings Inc. (TSX VENTURE:OGI)(OGRMF) (the “Company“) is pleased to announce that it has engaged Jacob Securities Inc. (the “Agent”) in connection with a proposed private placement (the “Offering), on a best efforts basis, whereby the Company intends to raise aggregate gross proceeds of a minimum of $4,000,000 and up to $6,000,000 at a price of $0.85 per unit. There is also an over-allotment option exercisable by the Agent prior to and for a period of 30 days following the Closing Date to raise additional gross proceeds of up to 15% of the maximum Offering.

Each unit will be comprised of one common share and one common share purchase warrant (the “Warrants”). Each Warrant will entitle the holder to purchase one additional common share of the Corporation at a price of $1.00 per share for a period of 36 months from the date of issue.

The Company will pay the Agent a commission of 6% cash (3% for Units issued through a Presidents List) on gross proceeds raised through the sale of the Units and issue broker warrants to acquire 6% (3% for Presidents List) of the total number of units issued, under this Offering. Each broker warrant will entitle the holder to subscribe for one common share of the Corporation at a price of $1.00 for a period of 24 months from the date of issue.

Proceeds from this Offering will be used by the Company to expedite the expansion of its medical marijuana facility in order to keep pace with the increase in demand for its products.

The anticipated closing of the Offering is December 12, 2014 (or such other date as may be agreed upon by the Company and the Agent).

Completion of this placement is subject to the approval of the TSX Venture Exchange.

About Organigram Holdings Inc.

Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Marihuana for Medical Purposes Regulations.

Please visit www.organigram.ca for more information.

On Behalf of the Board of Directors of Organigram,

Denis Arsenault, Director & CEO

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors – including the availability of funds, the results of financing efforts, the results of exploration activities — that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
OrganiGram Holdings Inc.
Brett Allan
Director of Investor Relations
(416) 907-4148
brett@organigram.ca

0 1825

Terra Tech Gives Update on Nevada Medical Cannabis Initiatives

MediFarm moving forward on opening MME facilities in Nevada

Las Vegas, Dec. 4, 2014 (GLOBE NEWSWIRE) — Terra Tech Corp. (TRTC) is pleased to update shareholders on its Nevada Medical Cannabis efforts. The company recently announced that MediFarm, MediFarm I, and MediFarm II, have all received provisional certificates from the State of Nevada in each local jurisdiction where they applied for a Medical Marijuana Establishment license. Collectively, these subsidiaries were issued a total of 4 Dispensary provisional certificates, 2 Cultivation provisional certificates and 2 Production provisional certificates spanning both Northern and Southern Nevada. Below is a summary of current status in each region:

City of Las Vegas Dispensary- MediFarm received a provisional registration certificate from the State of Nevada Department of Health and Human Services Division of Public and Behavioral Health on 11/3/2014. Subsequently, MediFarm submitted its Las Vegas Business License Application to the City of Las Vegas Department of Planning Business Licensing Division on 11/12/14. The application included documentation submitted to the Las Vegas Metro Police Department to initiate a second series of background checks for all owners of MediFarm. The Company is currently working with an architectural company and general contractor to design and ultimately submit final construction documents to the Las Vegas Building and Planning Departments for permitting. The company anticipates this process to take approximately 75 days. Once construction documents have been approved, MediFarm will begin construction. After completing construction and obtaining all required approvals and certifications from the local and state agencies, MediFarm will commence operations.

Clark County 2 Dispensaries, Cultivation and Production- MediFarm received four provisional registration certificates for 2 dispensaries, a cultivation and a production facility from the State of Nevada Department of Health and Human Services Division of Public and Behavioral Health on 11/3/2014. MediFarm also has received approval from the Clark County Department of Comprehensive Planning-Land Use Planning on June 25, 2014 for its cultivation and production facilities.

MediFarm has not yet received final approval from the Clark County Department of Comprehensive Planning-Land Use Planning for its two dispensaries and is awaiting a final determination from the Clark County Commissioners. The Clark County Commissioners voted to delay rendering a final determination 12/3/2014 due to litigation. Recently the company has been made aware that certain applicants in Clark County have filed a lawsuit naming the State of Nevada Department of Health and Human Services Division of Public and Behavioral Health as well as several other applicants. Terra Tech Subsidiary MediFarm was named but not yet served the lawsuit. For more info https://www.clarkcountycourts.us/Anonymous/default.aspx Case # A-14-710488C

This suit does not affect the company’s Clark County cultivation or production permits or any of thecompany’s initiatives in the other jurisdictions where it received provisional certificates.

The Company is currently working with an architectural company and general contractor to design and ultimately submit final construction documents to the Clark County Building and Planning Departments for permitting for all four facilities that have been issued provisional registration certificates from Nevada. Once we receive a determination from the Clark County Commission on final approval of our dispensary locations and after construction documents have been approved, MediFarm will begin construction on all premises that have been approved in Clark County. The company anticipates this process to take approximately 95 days, for the cultivation and production facilities, before construction begins. MediFarm will commence operations after completing construction and obtaining all required approvals and certifications from the local and state agencies.

Reno Dispensary- MediFarm I received a provisional registration certificate from the State of Nevada Department of Health and Human Services Division of Public and Behavioral Health on 11/3/2014. The Company is currently working to compile all the required documents necessary to submit a business license application to the City of Reno Business License Division. The Company is currently working with an architectural company and general contractor to design and ultimately submit final construction documents to the City of Reno Building, Planning and Engineering Division for permitting. The company anticipates this process to take approximately 80 days before construction begins. After completing construction and obtaining all required approvals and certifications from the local and state agencies, MediFarm I will commence operations.

Washoe County Cultivation and Production- MediFarm II received provisional registration certificates from the State of Nevada Department of Health and Human Services Division of Public and Behavioral Health on 11/3/2014. The Company is currently working to compile all the required documents necessary to submit a business license application to the Washoe County Business Department of Community Development. After completing construction and obtaining all required approvals and certifications from the local and state agencies, MediFarm II will commence operations. The company anticipates beginning construction within Q2 2015.

“The litigation in Clark County is potentially holding up opening our 2 dispensary locations and we will have to spend some effort navigating through the process. However, it is the cultivation and production facilities that take the most time to construct and a retail storefront is not needed until the Company is well into construction on those facilities. We were fortunate to receive approval in the City of Las Vegas for a retail dispensary and the Company is moving forward on that project. Even if Clark County decides not to approve any additional locations it appears that they will be left with only 10 storefronts. The State has said they will not issue any additional provisional certificates. This means either we get additional locations in the County or far less competition and greater potential market share for our City location,” explains Derek Peterson, CEO of Terra Tech. “The Company is thrilled at the opportunity we have within the state. With our multiple permits, we have all the state’s major markets covered regardless of what happens within Clark County. Our focus now is to aggressively work through the local administrative process and break ground as soon as possible. “

The Company will issue additional updates to investors in the near future as milestones are reached.

About Terra Tech

Terra Tech Corp. (TRTC) through its wholly-owned subsidiary GrowOp Technology, specializes in controlled environment agricultural technologies. The company integrates best-of-breed hydroponic equipment with proprietary software and hardware to provide sustainable solutions for indoor agriculture enterprises and home practitioners. Our complete product line is available at specialty retailers throughout the United States, and via our website. Through its wholly-owned subsidiary Edible Garden, cultivates a premier brand of local and sustainably grown hydroponic produce, sold through major grocery stores such as Shoprite, Food Emporium and others throughout New Jersey, New York, Delaware, Maryland, Connecticut, and Pennsylvania. MediFarm LLC is focused on medical cannabis businesses throughout Nevada.

For more information about Terra Tech Corp visit: www.terratechcorp.com

Visit us on Facebook @ http://www.facebook.com/terratechcorp

Follow us on Twitter @terratechcorp

For more information about Edible Garden visit: http://www.ediblegarden.com

Visit Edible Garden on Facebook @ https://www.facebook.com/ediblefarms

Cautionary Language Concerning Forward-Looking Statements

Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Terra Tech Corp.’s filings with the Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to Terra Tech Corp.’s (i) product demand, market and customer acceptance of its equipment and other goods, (ii) ability to obtain financing to expand its operations, (iii) ability to attract qualified sales representatives, (iv) competition, pricing and development difficulties, (v) ability to integrate GrowOp Technology Ltd. into its operations as a reporting issuer with the Securities and Exchange Commission, and (vi) general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on Terra Tech Corp.’s website does not constitute a part of this release.

Contact:
Bill Clayton
Independence Financial Ltd.
Toll-Free: (888) 603-2896
Email: info@terratechcorp.com

0 2036

Agritek Holdings Inc. CEO Featured on In-Depth Video Interview With CFN

LOS ANGELES, CA–(Marketwired – December 04, 2014) –  Agritek Holdings, Inc. (AGTK) (or the “Company”) (www.Agritekholdings.com), a fully reporting company on the OTCQB and leader in Compassionate Care Technology and indoor/outdoor agricultural solutions for the medicinal marijuana industry, today announced that its CEO, B. Michael Friedman recently conducted an in-depth video interview regarding the Company’s goals and path to sustainability within the medicinal cannabis sector which is now available for review at the following link:
http://www.cannabisfn.com/mdc/agritek-holdings-inc/

The video may additionally be viewed at:
https://vimeo.com/113342611

The Q&A interview released today under the headline “Agritek Holdings To Capitalize in Nevada MMJ Market” discusses the nature, significant competence and experience of its management team, the Company’s development of recreational medi-campuses and cultivation facilities in Nevada and Colorado, marketing innovation and strategies, as well the clinical significance of its approach and plans for both product commercialization and additional sector related revenue streams.

The article and video is part of an ongoing distribution of cannabis sector and related articles which have reached a number of industry and financial media outlets and the Company is very pleased to have the opportunity to access a growing audience interested in a well-considered, revenue-centric and recreational and medicinal cannabis REIT model and approach to the sector.

For more information about the Company please visit www.AgritekHoldings.com.

Additional details of the Company’s business, finances, appointments and agreements can be found as part of the Company’s continuous public disclosure as a fully reporting issuer with the Securities and Exchange Commission (“SEC”) available at www.sec.gov.

About Agritek Holdings, Inc.

Agritek Holdings, Inc. (www.Agritekholdings.com), the first fully reporting Company and pioneer within the medicinal marijuana space provides innovative patient and agricultural solutions seeks to be the leader in Compassionate Care Technology for the medicinal marijuana industry. Agritek Holdings provides real estate management and health and wellness product lines including vaporizers and accessories under the Mont Blunt™ brand (www.montblunt.com). Agritek Holdings Inc. does not directly grow, harvest, or distribute or sell cannabis or any substances that violate United States law or the Controlled Substances Act, nor does it intend to do so in the future.

About Cannabis Financial Network

The Cannabis Financial Network (“CannabisFN”) provides breaking news, expert interviews, and investment insights on emerging public companies in the cannabis and medical marijuana (“MMJ”) industry (www.cannabisfn.com). CFN also aims to inform both investors and corporate leaders about the fluid regulatory environment affecting the cannabis and medical marijuana industries. CannabisFN is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. All information provided is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Furthermore, investing in such securities involves substantial risk of loss and investors should seek advice from financial professionals before investing. CFN was compensated for its services in the form of cash-based compensation or equity securities, or a combination of the two. For a full disclaimer, click here.

FORWARD-LOOKING DISCLAIMER:

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Agritek Holdings, Inc. to be materially different from the statements made herein.

Contact:
Agritek Holdings, Inc.
561.249.6511
www.Agritekholdings.com
info@Agritekholdings.com

0 381

Nuvilex Announces the Opening of Austrianova’s cGMP Live Cell Encapsulation Facility in Thailand

SILVER SPRING, Md., Dec. 4, 2014 (GLOBE NEWSWIRE) — Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that Nuvilex executives joined Thailand government officials at the grand opening of Austrianova’s current Good Manufacturing Practices (cGMP) live-cell encapsulation facility within the Thai Science Park (TSP) in Bangkok, Thailand. The TSP is the premier Science, Technology and Innovation hub of Thailand and home to many leading international hi-tech and bio-tech companies.

Nuvilex contracted with its partner Austrianova to establish the manufacturing facility that will produce the Cell-in-a-Box(R) live-cell encapsulation product containing cancer prodrug-activating cells that will be used for the Phase 2b clinical trial of Nuvilex’s pancreatic cancer treatment in Australia and for clinical trials in the United States related to the intractable pain associated with pancreatic cancer and the accumulation of malignant ascites fluid that results from late-stage pancreatic cancer and other abdominal cancers. This facility will also be used to encapsulate insulin-producing cells that will be pivotal for clinical trials of Nuvilex’s treatment for insulin-dependent diabetes.

Nuvilex CEO and President, Kenneth L. Waggoner, stated, “Nuvilex is pleased that the new cGMP facility that will perform live cell encapsulation using the Cell-in-a-Box(R) encapsulation technology is officially open in Thailand. This is a vitally important event on the path to the new and later stage clinical trials for Nuvilex. We are pleased to have been invited as guest of honor at the grand opening ceremony and to have met with so many scientists and professors involved with the Cell-in-a-Box(R) technology.”

Dr. Brian Salmons, CEO and President of Austrianova, commented, “We are proud to have opened our unique cGMP facility which utilizes the first state-of-the-art, custom-built, controlled gaseous environment isolator based cell production system in Asia. This isolator system, housed in a newly built conventional Class D cleanroom, will ensure that all Cell-in-a-Box(R) products are manufactured to the highest international pharmaceutical production standards.”

Prof. Walter H. Gunzburg, Chief Scientific Officer of Nuvilex and Chairman of Austrianova, said, “Together with Thailand Center of Excellence in Life Sciences, we have worked for over a year to develop this world-first encapsulated cell production capability. Finally, through the close collaborative efforts of this Thai Government Agency with Austrianova and the Thailand Science Park, we have been able to achieve, in a remarkably short period, the realization of this unique facility.”

To view pictures of the event and the new facility in the Thai Science Park, visit:http://www.nuvilex.com/index.php?option=com_eventgallery&view=event&layout=tiles&folder=Event1&Itemid=133

About Nuvilex

Nuvilex (NVLX) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R). This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. Nuvilex’s treatment for pancreatic cancer involves the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or “cancer-killing” form. Nuvilex is also working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors. In addition, Nuvilex is developing treatments for cancers based upon cannabinoid-like drugs by examining ways to exploit the benefits of the Cell-in-a-Box(R) technology in optimizing the anticancer effectiveness of such drugs while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides Nuvilex a unique opportunity to develop “green” approaches to fighting cancers, such as those of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.

Safe Harbor

This press release may contain forward-looking statements regarding Nuvilex and its future events and results that involve inherent risks and uncertainties. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan” and similar expressions, as they relate to Nuvilex or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of Nuvilex, that could cause actual results to differ materially from those set forth in the forward-looking statements include Nuvilex’s ability to continue as a going concern, delays or unsuccessful results in clinical trials or flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of Nuvilex’s intellectual property and Nuvilex’s continued ability to raise capital. Nuvilex does not assume any obligation to update any of these forward-looking statements.

More information about Nuvilex can be found at www.nuvilex.com. It can also be obtained by contacting Investor Relations.

Contact:
Investor Relations Contacts:
Clare Matschullat
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 106
cmatschullat@bplifescience.com

0 321

MyECheck Appoints Jim Fancher as Executive Vice President

FOLSOM, Calif.–(BUSINESS WIRE)–MyECheck, Inc. (OTC PK: MYEC), the leader in electronic check solutions for internet and mobile payments, has named Jim Fancher as executive vice president. Fancher’s responsibilities will include implementing executive strategies and overseeing the company’s growth plan, including the expansion of top and bottom line revenues.

A proven financial industry veteran specializing in electronic check technology and related software development, Fancher holds a Bachelor of Science degree in computer engineering technology and has more than 15 years of highly relevant management and operational experience, having served in multiple senior level executive positions in the electronic check industry.

An industry leading expert in electronic check technology, Fancher’s experience includes serving as General Manager for Endpoint Exchange, an FIS company, where he had full P&L responsibility for the company’s real time, check image exchange that served more than six thousand financial institutions with an access of one hundred million electronic check image transactions per month. While at Endpoint Exchange, Fancher led the team that designed the first check image mining application, cultivated a partnership with IBM and the six largest US banks, and set the industry standards for check imaging resulting in viral adoption of mobile check deposit.

Prior to his time at Endpoint Exchange, Fancher has held senior sales or management positions at VectorSGI, Metavante, CheckFree/FiServ and other financial services software companies. Most recently, Fancher has been an operations and solutions consultant for SeerGate Ltd., where he created strategic partnership framework for the company.

“Jim’s unique expertise coupled with his strategic vision for MyECheck are invaluable assets to MyECheck, and we are excited for the future growth of the company under his leadership,” Ed Starrs, President and CEO.

About MyECheck: MyECheck Inc. is a leading electronic payment technology developer, licensor and payment services provider. MyECheck operates under license to US Patent 7,389,913, “Method and Apparatus for Online Check Processing” granted June 2008. This patented payment method is the fastest, most secure and most cost effective method of processing payments in the US. MyECheck provides comprehensive payment solutions for all payment applications including mobile payments and the industry’s most advanced security and fraud control technologies. MyECheck customers include corporations, retailers, governments, payment processors and financial institutions. For more information, contactsales@myecheck.com

Forward-looking statements in this release are made pursuant to “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of mentioned products, increased levels of competition, new products and technological changes, dependence upon third-party suppliers, intellectual property rights, and other risks detailed from time to time in reports filed with the SEC.

Contact:
Payments/Banking Media
Rebecca Mayo, 678-781-7221
rebecca@williammills.com
or
MyECheck Investor Relations
Bill Delgado
bill.delgado@myecheck.com

0 330

Cannabis Science (CBIS) Readies To Launch New Products In California With Apothocary Genetics

COLORADO SPRINGS, Colo., Dec. 5, 2014 /PRNewswire/ — Cannabis Science, Inc. (CBIS), a U.S. company specializing in global cannabis formulation-based drug development and consulting, is in the final stages of its preparations to launch new products throughout the California market, including extracts, oils, tinctures, tablets, and creams.

“All that’s left now is to finish work on the packaging and the labeling, and that should only take a matter of days,” said Mr. Raymond C. Dabney, Director, President & CEO and Co-Founder of Cannabis Science Inc. “The products and the formulation are there. We’re ready to launch in California and we’re excited, as I’m sure many self-medicating patients are.”

The California launch was made possible by a renegotiation of the Cannabis Science agreement with Apothecary Genetics Investments LLC. The new agreement enabled Cannabis Science to purchase and license two northern California production farms with a combined total of 51 acres. The purchase included all related equipment for cannabis cultivation and production for the state’s substantial medical cannabis market and gives Apothecary Genetics the right to sell Cannabis Science formulations throughout the State of California.

“Apothecary Genetics is state licensed and regulated, and now with our new licensing agreement we can proceed with the commercialization of our medical cannabis formulations throughout the State,” said Mr. Dabney.

Mr. Dabney said the company will provide more information about the release of its products and where they will be available in the coming days.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Raymond C. Dabney, Director, President & CEO, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788

Chad S. Johnson, Esq., Director, COO, & General Counsel
www.cannabisscience.com
info@cannabisscience.com
1.888.777.0658

0 395

Photo Release — CanChew Gum Receives Triple Leaf Award

Healthy Living Magazine Educates 835,000 Readers on Cannabidiol (CBD)

SAN DIEGO, Dec. 3, 2014 (GLOBE NEWSWIRE) — Medical Marijuana, Inc. (OTC Pink:MJNA), a leading cannabis and industrial hemp industry innovator, is proud to announce that its joint venture company, CanChew Biotechnologies, LLC (CanChew(R)), was honored by HealthyLivinG Foundation with its Triple Leaf Award. CanChew(R), a hemp cannabidiol (CBD) oil-infused chewing gum, is also featured in Healthy Living Magazine‘s December issue reaching its more than 835,000 readers and social media followers.

Photos accompanying this release are available at

http://www.globenewswire.com/newsroom/prs/?pkgid=29444

http://www.globenewswire.com/newsroom/prs/?pkgid=29445

http://www.globenewswire.com/newsroom/prs/?pkgid=29446

“The acceptance of CanChew(R), a hemp CBD-infused chewing gum, by the prestigious consumer safety organization HealthyLivinG Foundation is a major step forward for the industrial hemp industry,” states Michelle Sides, Chief Operating Officer of Medical Marijuana, Inc. “We are extremely proud that CanChew(R) gum received HealthyLivinG Foundation‘s Triple Leaf Award. Our Company invests in bringing to market innovative industrial hemp-based products. The Triple Leaf Award is validation of why MJNA chose to form a joint venture CanChew(R) as a portfolio company.”

Andrew Hard, Spokesperson for Medical Marijuana, Inc. states, “Consumer safety is a top priority for MJNA. The Triple Leaf Award for CanChew(R) emphasizes this core belief and we are very proud to share the news of this prestigious industry award. What an unexpected holiday surprise, and what a prestigious award for CanChew(R). Fans of CanChew(R) this is just the beginning. Stay tuned closely in 2015 as we have a lot more news on the way.”

HealthyLivinG Foundation‘s website classifies its Triple Leaf Award as follows:

  • Personal Safety Criteria
    • Green: absence of chemicals likely to cause acute or chronic toxicity
    • Yellow: presence of chemicals likely to cause acute toxicity (allergies, irritation, sensitization)
    • Red: presence of chemicals likely to cause acute (allergies, irritation, sensitization) and chronic (cancer, birth defects, reproductive, genetic, neurological) toxic effects
  • Environmental Criteria
    • Green: disposal not likely to pollute air, water or soil; recycled packaging; avoids pesticide usage (organic); humane farm practices (when applicable); absence of petrochemicals, heavy metals; resource sustainability; no GMOs; environmental controls at site of manufacture.
    • Yellow: some or none recycled packaging content; petrochemical-based ingredients (when alternatives exist); lacking resource sustainability and cradle to grave accountability.
    • Red: disposal likely to pollute air, water or soil; non- or minimally recycled packaging; petrochemicals; pesticides; factory farming (when applicable); lacking resource sustainability and environmental safeguards at site of manufacture.
  • Social Responsibility Criteria
    • Green: reducing pollution; carbon neutral; human rights; fair trade; technological breakthroughs; environmental stewardship; philanthropy; sustainable resources.
    • Yellow: lacking programs for pollution and carbon reduction; non-sustainable sourcing; absence of fair trade policies.
    • Red: increasing pollution; destructive environmental practices; human rights violations; labor exploitation; lacking meaningful environmental stewardship.

Sides concludes, “We are thrilled that Healthy Living Magazine educated its readers on cannabidiol or CBD. This article provides further proof that interest in cannabis consumer products are on the rise. We feel that the tides are quickly turning for this highly revered ancient plant in the global marketplace.”

For more information visit the Company’s website at www.canchewbiotech.com.

About Medical Marijuana, Inc.

Our mission is to be the premier hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company’s website at:www.MedicalMarijuanaInc.com.

About CanChew Biotechnologies

CanChew Biotechnologies focuses on the treatment of pain and other medical disorders with the application of cannabinoid medical products as well as food and nutraceutical products for general well-being.

The company is focused on the R&D and execution of their clinical development plan and potential out-licensing of their technology. Clinical development focuses on the R&D of the formulation, production and the development of chewing gum-based products for the treatment of conditions like pain, nausea and vomiting, anorexia, spasticity and various other medical issues. For more information on the company, visit CanChewBiotech.com.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE

Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The Company does grow, sell and distribute hemp-based products and are involved with the federally legal distribution of hemp-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.

The photos are also available at Newscom, www.newscom.com, and via AP PhotoExpress.

Contact:
For further information, please contact:
Investor Relations contact:
Perry Coleman
Medical Marijuana, Inc.
P. 443-453-5088
perry@medicalmarijuanainc.com
Public Relations contact:
Andrew Hard
Spokesperson
P. 858-380-5478
Corporate contact:
Medical Marijuana, Inc.
Toll Free: 888-OTC-MJNA (888-682-6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements